PARP Cancer Research Results

PARP, poly ADP-ribose polymerase (PARP) cleavage: Click to Expand ⟱
Source:
Type:
Poly (ADP-ribose) polymerase (PARP) cleavage is a hallmark of caspase activation. PARP (Poly (ADP-ribose) polymerase) is a family of proteins involved in a variety of cellular processes, including DNA repair, genomic stability, and programmed cell death. PARP enzymes play a crucial role in repairing single-strand breaks in DNA.
PARP has gained significant attention, particularly in the treatment of certain types of tumors, such as those with BRCA1 or BRCA2 mutations. These mutations impair the cell's ability to repair double-strand breaks in DNA through homologous recombination. Cancer cells with these mutations can become reliant on PARP for survival, making them particularly sensitive to PARP inhibitors.
PARP inhibitors, such as olaparib, rucaparib, and niraparib, have been developed as targeted therapies for cancers associated with BRCA mutations.

PARP Family:
The poly (ADP-ribose) polymerases (PARPs) are a family of enzymes involved in a number of cellular processes, including DNA repair, genomic stability, and programmed cell death.
PARP1 is the predominant family member responsible for detecting DNA strand breaks and initiating repair processes, especially through base excision repair (BER).

PARP1 Overexpression:
In several cancer types—including breast, ovarian, prostate, and lung cancers—elevated PARP1 expression and/or activity has been reported.
High PARP1 expression in certain cancers has been associated with aggressive tumor behavior and resistance to therapies (especially those that induce DNA damage).
Increased PARP1 activity may correlate with poorer overall survival in tumors that rely on DNA repair for survival.
Scientific Papers found: Click to Expand⟱
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
2232- SK,    Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis
- in-vitro, ESCC, EC9706
tumCV↓, TumCMig↓, TumCI↓, TumAuto↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑PARP↑, AMPK↑, mTOR↑, TumVol↓, OS↑, LC3I↑,
2228- SK,    Shikonin induced Apoptosis Mediated by Endoplasmic Reticulum Stress in Colorectal Cancer Cells
- in-vitro, CRC, HCT116 - in-vitro, CRC, HCT15 - in-vivo, NA, NA
Apoptosis↑, Bcl-2↓, Casp3↑, Casp9↑, cl‑PARP↑, GRP78/BiP↑, PERK↑, eIF2α↑, ATF4↑, CHOP↑, JNK↑, eff↓, ER Stress↑, ROS↑, TumCG↓,
3047- SK,    Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL-6/STAT3 signaling pathway
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
TumCG↓, p‑STAT3↓, ADAM17↓, Apoptosis↑, Casp3↑, cl‑PARP↑, cycD1/CCND1↓, cycE/CCNE↓, TumCCA↑, JAK1?, p‑JAK1↓, p‑JAK2↓, p‑eIF2α↑, eff↓, ROS↑, IL6↓,
2469- SK,    Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2
- in-vitro, Lung, H1975
Apoptosis↑, Pyro↑, Casp↑, cl‑PARP↑, GSDME↑, ROS↑, COX2↓, PDK1↓, Akt↓, ERK↓, eff↓, eff↓, eff↑,
1344- SK,    Novel multiple apoptotic mechanism of shikonin in human glioma cells
- in-vitro, GBM, U87MG - in-vitro, GBM, Hs683 - in-vitro, GBM, M059K
ROS↑, GSH↓, MMP↓, P53↑, cl‑PARP↑, Catalase↓, SOD1↑, Bcl-2↓, BAX↑, eff↓,
1312- SK,    Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells
- in-vitro, OS, 143B
ROS↑, p‑ERK↑, Bcl-2↓, cl‑PARP↑, Apoptosis↑, TumCCA↑, Bcl-2↑, proCasp3↓,
2010- SK,    Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway
- in-vitro, Lung, H1975 - in-vitro, Lung, H1650 - in-vitro, Nor, CCD19
EGFR↓, selectivity↑, Casp↑, PARP↑, Apoptosis↑, ROS↑, eff↓, selectivity↑,
1002- SSE,  Osi,  Adag,    Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference
- in-vitro, Lung, H1975 - in-vitro, Lung, H385
Apoptosis↑, Ferroptosis↑, DNMT1↓, TET1↑, TumCCA↑, cl‑PARP↑, cl‑Casp3↑, Cyt‑c↑, BIM↑, NOXA↑, Apoptosis↑, ROS↑, ER Stress↑, UPR↑,
5331- TFdiG,    Anti-Cancer Properties of Theaflavins
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, cl‑PARP↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, BAX↑, Bcl-2↓, p‑Akt↓, p‑mTOR↓, PI3K↓, cMyc↓, P53↑, ROS↑, NF-kB↓, MMP9↓, MMP2↓, TumVol↓, PSA↓, TumCCA↑, VEGF↓, Hif1a↓, CDK2↓, CDK4↓, GSH↓, Dose↑, BioAv↓, BioAv↓, BioAv↑,
2123- TQ,    Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma
- in-vitro, lymphoma, PEL
Akt↓, ROS↑, BAX↓, MMP↓, Cyt‑c↑, eff↑, Casp9↑, Casp3↑, cl‑PARP↑, DR5↑,
2127- TQ,    Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways
- Review, GBM, NA
chemoP↑, ChemoSen↑, BioAv↑, PTEN↑, PI3K↓, Akt↓, TumCCA↓, NF-kB↓, p‑Akt↓, p65↓, XIAP↓, Bcl-2↓, COX2↓, VEGF↓, mTOR↓, RAS↓, Raf↓, MEK↓, ERK↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, Casp↑, cl‑PARP↑, ROS⇅, ROS↑, MMP↓, eff↑, Telomerase↓, DNAdam↑, Apoptosis↑, STAT3↓, RadioS↑,
2129- TQ,  doxoR,    Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells
- in-vitro, BC, MCF-7
ChemoSen↑, PTEN↑, p‑Akt↓, TumCCA↑, P53↑, P21↑, Apoptosis↑, MMP↓, Casp↑, cl‑PARP↑, Bax:Bcl2↑, eff↓, DNAdam↓, p‑γH2AX↑, ROS↑,
2097- TQ,    Crude extract of Nigella sativa inhibits proliferation and induces apoptosis in human cervical carcinoma HeLa cells
- in-vitro, Cerv, HeLa
Cyt‑c↑, Bax:Bcl2↑, Casp3↑, Casp9↑, Casp8↑, cl‑PARP↑, cMyc↓, hTERT/TERT↓, cycD1/CCND1↓, CDK4↓, P53↑, P21↑, TumCP↓, Apoptosis↓, selectivity↑,
2084- TQ,    Thymoquinone, as an anticancer molecule: from basic research to clinical investigation
- Review, Var, NA
*ROS↓, *chemoPv↑, ROS↑, ROS⇅, MUC4↓, selectivity↑, AR↓, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, survivin↓, Mcl-1↓, VEGF↓, cl‑PARP↑, ROS↑, HSP70/HSPA5↑, P53↑, miR-34a↑, Rac1↓, TumCCA↑, NOTCH↓, NF-kB↓, IκB↓, p‑p65↓, IAP1↓, IAP2↑, XIAP↓, TNF-α↓, COX2↓, Inflam↓, α-tubulin↓, Twist↓, EMT↓, mTOR↓, PI3K↓, Akt↓, BioAv↓, ChemoSen↑, BioAv↑, PTEN↑, chemoPv↑, RadioS↑, *Half-Life↝, *BioAv↝,
2085- TQ,    Anticancer Activities of Nigella Sativa (Black Cumin)
- Review, Var, NA
MMP↓, Casp3↑, Casp8↑, Casp9↓, cl‑PARP↑, Cyt‑c↑, Bax:Bcl2↑, NF-kB↓, IAP1↓, IAP2↓, XIAP↓, Bcl-xL↓, survivin↓, cJun↑, p38↑, Akt↑, chemoP↑, *radioP↑,
2095- TQ,    Review on the Potential Therapeutic Roles of Nigella sativa in the Treatment of Patients with Cancer: Involvement of Apoptosis
- Review, Var, NA
TumCCA↑, Apoptosis↑, ROS↑, Cyt‑c↑, Bax:Bcl2↑, Casp3↑, Casp9↑, cl‑PARP↑, P53↑, P21↑, cMyc↓, hTERT/TERT↓, cycD1/CCND1↓, CDK4↓, NF-kB↓, IAP1↓, IAP2↓, XIAP↓, Bcl-xL↓, survivin↓, COX2↓, MMP9↓, VEGF↓, eff↑,
2108- TQ,    Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa
- Review, Var, NA
HDAC↓, TumCCA↑, cycD1/CCND1↓, p16↑, P53↑, Bax:Bcl2↑, Bcl-xL↓, NF-kB↓, IAP1↓, IAP2↓, XIAP↓, survivin↓, COX2↓, cMyc↓, ROS↑, Casp3↑, cl‑PARP↑, Cyt‑c↑, STAT3↓,
3413- TQ,    Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src‑mediated phosphorylation of EGF receptor tyrosine kinase
- in-vitro, CRC, HCT116
tumCV↓, Apoptosis↓, BAX↑, Bcl-2↓, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, STAT3↓, survivin↓, cMyc↓, cycD1/CCND1↓, p27↑, P21↑, EGFR↓, ROS↑,
3414- TQ,    Thymoquinone induces apoptosis through inhibition of JAK2/STAT3 signaling via production of ROS in human renal cancer Caki cells
- in-vitro, RCC, Caki-1
tumCV↓, Apoptosis↑, P53↑, BAX↑, Cyt‑c↑, cl‑Casp9↑, cl‑Casp3↑, cl‑PARP↑, Bcl-2↓, Bcl-xL↓, p‑STAT3↓, p‑JAK2↓, STAT3↓, survivin↓, cycD1/CCND1↓, ROS↑, eff↓,
3397- TQ,    Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
ChemoSen↑, *Half-Life↝, *BioAv↝, *antiOx↑, *Inflam↓, *hepatoP↑, TumCP↓, TumCCA↑, Apoptosis↑, angioG↑, selectivity↑, JNK↑, p38↑, p‑NF-kB↑, ERK↓, PI3K↓, PTEN↑, Akt↓, mTOR↓, EMT↓, Twist↓, E-cadherin↓, ROS⇅, *Catalase↑, *SOD↑, *GSTA1↑, *GPx↑, *PGE2↓, *IL1β↓, *COX2↓, *MMP13↓, MMPs↓, TumMeta↓, VEGF↓, STAT3↓, BAX↑, Bcl-2↑, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, survivin↓, cMyc↓, cycD1/CCND1↓, p27↑, P21↑, GSK‐3β↓, β-catenin/ZEB1↓, chemoP↑,
3422- TQ,    Thymoquinone, as a Novel Therapeutic Candidate of Cancers
- Review, Var, NA
selectivity↑, P53↑, PTEN↑, NF-kB↓, PPARγ↓, cMyc↓, Casp↑, *BioAv↓, BioAv↝, eff↑, survivin↓, Bcl-xL↓, Bcl-2↓, Akt↓, BAX↑, cl‑PARP↑, CXCR4↓, MMP9↓, VEGFR2↓, Ki-67↓, COX2↓, JAK2↓, cSrc↓, Apoptosis↑, p‑STAT3↓, cycD1/CCND1↓, Casp3↑, Casp7↑, Casp9↑, N-cadherin↓, Vim↓, Twist↓, E-cadherin↑, ChemoSen↑, eff↑, EMT↓, ROS↑, DNMT1↓, eff↑, EZH2↓, hepatoP↑, Zeb1↓, RadioS↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, *NAD↑, *SIRT1↑, SIRT1↓, *Inflam↓, *CRP↓, *TNF-α↓, *IL6↓, *IL1β↓, *eff↑, *MDA↓, *NO↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, PI3K↓, mTOR↓,
3416- TQ,    Thymoquinone induces apoptosis in bladder cancer cell via endoplasmic reticulum stress-dependent mitochondrial pathway
- in-vitro, Bladder, T24/HTB-9 - in-vitro, Bladder, 253J - in-vitro, Nor, SV-HUC-1
TumCP↓, Apoptosis↑, ER Stress↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp7↑, cl‑PARP↑, Cyt‑c↑, PERK↑, IRE1↑, ATF6↑, p‑eIF2α↑, ATF4↑, GRP78/BiP↑, CHOP↑,
3415- TQ,    The anti-neoplastic impact of thymoquinone from Nigella sativa on small cell lung cancer: In vitro and in vivo investigations
- in-vitro, Lung, H446
tumCV↓, TumCCA↑, ROS↓, CycB/CCNB1↑, CycD3↑, cycA1/CCNA1↓, cycE/CCNE↓, cDC2↓, antiOx↑, PARP↓, NRF2↓, ARE/EpRE↑, eff↑,
5904- TV,    Pharmacological Properties and Molecular Mechanisms of Thymol: Prospects for Its Therapeutic Potential and Pharmaceutical Development
- Review, Var, NA - Review, Stroke, NA - Review, Diabetic, NA - Review, Obesity, NA - Review, AD, NA - Review, Arthritis, NA
*antiOx↑, *ROS↓, *Inflam↓, *Bacteria↓, AntiTum↑, IronCh↑, *HDL↑, *LDL↓, *BioAv↝, *Half-Life↝, *BioAv↑, *SOD↑, *GPx↑, *GSTs↑, *eff↑, radioP↑, *MDA↓, *other↑, *COX1↓, *COX2↓, *AntiAg↑, *RNS↓, *NO↓, *H2O2↓, *NOS2↓, *NADH↓, *Imm↑, Apoptosis↑, TumCP↓, angioG↓, TumCMig↓, Ca+2↑, TumCCA↑, DNAdam↑, BAX↑, Casp9↑, Casp8↑, Casp3↑, cl‑PARP↑, AIF↑, i-ROS↑, MMP↓, Cyt‑c↑, APAF1↑, Ca+2↑, MMP9↓, MMP2↓, PKCδ↓, ERK↓, H2O2↑, BAX↑, Bcl-2↓, DNAdam↑, lipid-P↑, ChemoSen↑, chemoP↑, *cardioP↑, *SOD↑, *Catalase↑, *GPx↑, *GSH↑, *BP↓, *AntiDiabetic↑, *Obesity↓, RenoP↑, *GastroP↑, hepatoP↑, *AChE↓, *cognitive↑, *BChE↓, *other↓, *BioAv↑,
1310- UA,    Ursolic acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast cancer cells
- in-vitro, BC, MCF-7
GR↝, AP-1↝, cl‑PARP↑, Bcl-2↓,
1020- UA,    Root Bark of Morus alba L. and Its Bioactive Ingredient, Ursolic Acid, Suppress the Proliferation of Multiple Myeloma Cells by Inhibiting Wnt/β-Catenin Pathway
- in-vitro, Melanoma, RPMI-8226
β-catenin/ZEB1↓, TCF↓, cMyc↓, cycD1/CCND1↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, cl‑PARP↑, Casp7↑,
4856- Uro,    Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro
- in-vitro, NPC, CNE1 - in-vitro, NPC, CNE2
Apoptosis↑, MMP↓, ROS↑, E-cadherin↑, BAX↑, cl‑Casp3↑, PARP↑, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, Snail↓, eff↓, TumCP↓, TumCMig↓, TumCI↓, EMT↓,
4837- Uro,    Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review
- Review, Var, NA
AntiCan↑, TumCCA↑, Apoptosis↑, TumAuto↑, *BioAv↝, *BioAv↑, RAS↓, ERK↓, AR↓, TumCP↓, PI3K↓, Akt↓, NF-kB↓, COX2↓, IL6↓, IL1β↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, P53↑, Casp3↑, PARP↑, ROS↓, toxicity↓,
4468- VitC,  SSE,    Selenium modulates cancer cell response to pharmacologic ascorbate
- in-vivo, GBM, U87MG - in-vitro, CRC, HCT116
eff↓, TumCD↑, ChemoSen↑, ROS⇅, DNAdam↑, PARP↑, NAD↓, Glycolysis↓, Fenton↑, lipid-P↑, eff↓, H2O2↑, other↝,
627- VitC,    High-Dose Vitamin C for Cancer Therapy
- Review, NA, NA
ROS↑, PARP↑, GAPDH↓, DNAdam↑, ATP↓,
633- VitC,    Diverse antitumor effects of ascorbic acid on cancer cells and the tumor microenvironment
- Analysis, NA, NA
Fenton↑, ROS↑, EMT↓, DNAdam↑, PARP↑, NAD↓, ATP↓, Apoptosis↑,
632- VitC,    High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients
- Review, NA, NA
SVCT-2∅, ROS↑, Hif1a↓, PARP∅, TET2↑,
3138- VitC,    The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity
- in-vitro, RCC, RCC4 - in-vitro, CRC, HCT116 - in-vitro, BC, MDA-MB-435 - in-vitro, Ovarian, SKOV3 - in-vitro, Colon, SW48 - in-vitro, GBM, U251
eff↑, Warburg↓, BioAv↑, ROS↑, DNAdam↑, ATP↓, eff↑, necrosis↑, PARP↑,
3133- VitC,    Vitamin C supplementation had no side effect in non-cancer, but had anticancer properties in ovarian cancer cells
- in-vitro, Ovarian, NA
*SVCT-2↑, *GLUT1↓, SVCT-2↓, GLUT1↑, TumCP↓, CDK2↓, PARP↓, selectivity↑,

Showing Research Papers: 251 to 285 of 285
Prev Page 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 285

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   ARE/EpRE↑, 1,   Catalase↓, 1,   Fenton↑, 2,   Ferroptosis↑, 1,   GSH↓, 2,   H2O2↑, 2,   lipid-P↑, 2,   NRF2↓, 1,   ROS↓, 2,   ROS↑, 24,   ROS⇅, 4,   i-ROS↑, 1,   SOD1↑, 1,   TrxR1↓, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   ATP↓, 3,   MEK↓, 1,   MMP↓, 7,   Raf↓, 1,   XIAP↓, 5,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   cMyc↓, 9,   GAPDH↓, 1,   Glycolysis↓, 1,   NAD↓, 2,   PDK1↓, 1,   PKM2↓, 1,   PPARγ↓, 1,   SIRT1↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 8,   Akt↑, 1,   p‑Akt↓, 3,   APAF1↑, 1,   Apoptosis↓, 2,   Apoptosis↑, 22,   ATF2↓, 1,   BAX↓, 1,   BAX↑, 10,   Bax:Bcl2↑, 5,   Bcl-2↓, 12,   Bcl-2↑, 2,   Bcl-xL↓, 6,   BIM↑, 1,   Casp↑, 5,   Casp3↑, 13,   cl‑Casp3↑, 7,   proCasp3↓, 1,   Casp7↑, 4,   cl‑Casp7↑, 2,   Casp8↑, 3,   cl‑Casp8↑, 3,   Casp9↓, 1,   Casp9↑, 8,   cl‑Casp9↑, 2,   Cyt‑c↑, 9,   DR5↑, 1,   Ferroptosis↑, 1,   GRP58↓, 1,   GSDME↑, 1,   hTERT/TERT↓, 2,   IAP1↓, 4,   IAP2↓, 3,   IAP2↑, 1,   JNK↑, 2,   p‑JNK↑, 1,   Mcl-1↓, 1,   Necroptosis↑, 1,   necrosis↑, 1,   NOXA↑, 1,   p27↑, 2,   p38↑, 2,   p‑p38↑, 1,   Pyro↑, 1,   RIP1↓, 1,   survivin↓, 8,   Telomerase↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

cSrc↓, 1,  

Transcription & Epigenetics ⓘ

cJun↑, 1,   EZH2↓, 1,   other↝, 1,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

ATF6↑, 1,   CHOP↑, 2,   eIF2α↑, 1,   p‑eIF2α↑, 2,   ER Stress↑, 3,   GRP78/BiP↑, 2,   HSP70/HSPA5↑, 1,   IRE1↑, 1,   PERK↑, 2,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

LC3I↑, 1,   TumAuto↑, 3,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,   DNAdam↑, 7,   DNMT1↓, 2,   p16↑, 1,   P53↑, 10,   PARP↓, 2,   PARP↑, 7,   PARP∅, 1,   cl‑PARP↑, 25,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 2,   CDK4↓, 3,   cycA1/CCNA1↓, 1,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 10,   CycD3↑, 1,   cycE/CCNE↓, 2,   P21↑, 5,   TumCCA↓, 1,   TumCCA↑, 13,  

Proliferation, Differentiation & Cell State ⓘ

cDC2↓, 1,   EMT↓, 5,   ERK↓, 5,   p‑ERK↓, 1,   p‑ERK↑, 1,   GSK‐3β↓, 1,   HDAC↓, 2,   HDAC1↓, 1,   HDAC2↓, 1,   HDAC3↓, 1,   miR-34a↑, 1,   mTOR↓, 5,   mTOR↑, 1,   p‑mTOR↓, 1,   NOTCH↓, 1,   PI3K↓, 7,   PTEN↑, 5,   RAS↓, 2,   Src↓, 1,   STAT3↓, 5,   p‑STAT3↓, 3,   TCF↓, 1,   TumCG↓, 2,   Wnt↓, 1,  

Migration ⓘ

AP-1↝, 1,   Ca+2↑, 2,   E-cadherin↓, 1,   E-cadherin↑, 2,   FAK↓, 1,   Ki-67↓, 1,   MMP2↓, 4,   MMP9↓, 6,   MMPs↓, 2,   MUC4↓, 1,   N-cadherin↓, 2,   PKCδ↓, 1,   Rac1↓, 1,   RIP3↓, 1,   Snail↓, 1,   TET1↑, 1,   TumCI↓, 3,   TumCMig↓, 6,   TumCP↓, 10,   TumMeta↓, 1,   Twist↓, 3,   Vim↓, 2,   Zeb1↓, 1,   α-tubulin↓, 1,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   angioG↑, 1,   ATF4↑, 2,   EGFR↓, 2,   Hif1a↓, 2,   VEGF↓, 5,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

GLUT1↑, 1,   SVCT-2↓, 1,   SVCT-2∅, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 7,   CXCR4↓, 1,   IL1β↓, 1,   IL6↓, 2,   Inflam↓, 1,   IκB↓, 1,   JAK1?, 1,   p‑JAK1↓, 1,   JAK2↓, 1,   p‑JAK2↓, 2,   NF-kB↓, 8,   p‑NF-kB↑, 1,   p65↓, 1,   p‑p65↓, 1,   PSA↓, 1,   TNF-α↓, 1,  

Cellular Microenvironment ⓘ

ADAM17↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,   GR↝, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 4,   BioAv↝, 1,   ChemoSen↑, 7,   Dose↑, 1,   eff↓, 11,   eff↑, 10,   RadioS↑, 3,   selectivity↑, 7,   TET2↑, 1,  

Clinical Biomarkers ⓘ

AR↓, 2,   EGFR↓, 2,   EZH2↓, 1,   hTERT/TERT↓, 2,   IL6↓, 2,   Ki-67↓, 1,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 3,   AntiTum↑, 1,   chemoP↑, 4,   chemoPv↑, 1,   hepatoP↑, 2,   OS↑, 1,   radioP↑, 1,   RenoP↑, 1,   toxicity↓, 1,   TumVol↓, 2,  
Total Targets: 222

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 3,   GPx↑, 4,   GSH↑, 2,   GSTA1↑, 1,   GSTs↑, 1,   H2O2↓, 1,   HDL↑, 1,   MDA↓, 2,   NADH↓, 1,   RNS↓, 1,   ROS↓, 2,   SOD↑, 4,  

Core Metabolism/Glycolysis ⓘ

LDL↓, 1,   NAD↑, 1,   SIRT1↑, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,   other↑, 1,  

Migration ⓘ

AntiAg↑, 1,   MMP13↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 2,  

Barriers & Transport ⓘ

GastroP↑, 1,   GLUT1↓, 1,   SVCT-2↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 1,   COX2↓, 2,   CRP↓, 1,   IL1β↓, 2,   IL6↓, 1,   Imm↑, 1,   Inflam↓, 3,   PGE2↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   BChE↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 3,   BioAv↝, 4,   eff↑, 2,   Half-Life↝, 3,  

Clinical Biomarkers ⓘ

BP↓, 1,   CRP↓, 1,   IL6↓, 1,   NOS2↓, 1,  

Functional Outcomes ⓘ

AntiDiabetic↑, 1,   cardioP↑, 1,   chemoPv↑, 1,   cognitive↑, 1,   hepatoP↑, 1,   Obesity↓, 1,   radioP↑, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 1,  
Total Targets: 52

Scientific Paper Hit Count for: PARP, poly ADP-ribose polymerase (PARP) cleavage
16 Apigenin (mainly Parsley)
15 Curcumin
14 Thymoquinone
12 Baicalein
12 Quercetin
12 Fisetin
10 Sulforaphane (mainly Broccoli)
8 EGCG (Epigallocatechin Gallate)
8 Shikonin
7 Ashwagandha(Withaferin A)
7 Berberine
7 Capsaicin
6 Boswellia (frankincense)
6 Carnosic acid
6 Garcinol
6 Honokiol
6 Piperlongumine
6 Vitamin C (Ascorbic Acid)
5 Metformin
5 Betulinic acid
5 Chrysin
5 Emodin
5 Silymarin (Milk Thistle) silibinin
4 doxorubicin
4 Bufalin/Huachansu
4 Carvacrol
4 Citric Acid
4 Gambogic Acid
4 Propolis -bee glue
4 Phenethyl isothiocyanate
4 Resveratrol
3 Auranofin
3 Allicin (mainly Garlic)
3 Cisplatin
3 Brucea javanica
3 Thymol-Thymus vulgaris
3 Docetaxel
3 Ellagic acid
3 Magnetic Fields
3 Propyl gallate
2 Silver-NanoParticles
2 5-fluorouracil
2 Artemisinin
2 Berbamine
2 temozolomide
2 brusatol
2 Boron
2 Radiotherapy/Radiation
2 HydroxyTyrosol
2 Juglone
2 Luteolin
2 Lycopene
2 Magnolol
2 Nimbolide
2 Phenylbutyrate
2 Paclitaxel
2 Piperine
2 Rosmarinic acid
2 salinomycin
2 Selenite (Sodium)
2 Ursolic acid
2 Urolithin
1 3-bromopyruvate
1 immunotherapy
1 Atorvastatin
1 Aloe anthraquinones
1 Baicalin
1 almonertinib
1 Bromelain
1 Butyrate
1 Sorafenib (brand name Nexavar)
1 Cat’s Claw
1 Celastrol
1 Chlorogenic acid
1 Chlorophyllin
1 Coenzyme Q10
1 Dichloroacetophenone(2,2-)
1 Dichloroacetate
1 Fucoidan
1 Ferulic acid
1 Gallic acid
1 Gemcitabine (Gemzar)
1 Graviola
1 Hydroxycinnamic-acid
1 hydroxychloroquine
1 lambertianic acid
1 Methylene blue
1 Photodynamic Therapy
1 Chemotherapy
1 Myricetin
1 nelfinavir/Viracept
1 Oleuropein
1 SonoDynamic Therapy UltraSound
1 Hyperthermia
1 Plumbagin
1 VitK3,menadione
1 Hyperoside
1 Selenium NanoParticles
1 chitosan
1 Folic Acid, Vit B9
1 Osimertinib
1 Adagrasib
1 Aflavin-3,3′-digallate
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:239  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page